Avidity Biosciences, Inc. announced that Arthur A. Levin, Ph.D. has been appointed to the board of directors of the company and is transitioning from chief scientific officer into the role of distinguished scientist and strategic leader, remaining a key member of Avidity's team. W. Michael Flanagan, Ph.D., has been promoted from chief technical officer to chief scientific and technical officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.64 USD | -0.80% | +49.02% | +338.01% |
Jun. 14 | Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating | MT |
Jun. 14 | Avidity Biosciences Prices $400.9 Million Offering of Shares | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+338.01% | 4.21B | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Announces Changes to Its Board